Biomarin Pharmaceutical (BMRN) Operating Margin (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Operating Margin came in at 16.92% in Q1 2026, down 1313.0% YoY from 1.39% in Q1 2025, and up 431.71% on a QoQ basis from 5.1% in Q4 2025.
Biomarin Pharmaceutical (BMRN) Operating Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Operating Margin data on file, last reported at 16.92% in Q1 2026.
- Quarterly Operating Margin fell 1313.0% year-over-year to 16.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.72% (down 1128.0% YoY) and the FY2025 annual result came in at 12.71%, down 425.0% from the prior year.
- Operating Margin climbed to 16.92% in Q1 2026, from 5.1% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 33.55% in Q2 2025 to a low of 6.02% in Q3 2025.
- A 5-year average of 11.68% and a median of 11.01% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin surged 2128 bps — and 2025, when it sank 2670 bps.
- Tracing BMRN's Operating Margin over 5 years: stood at 2.43% in 2022, then surged by 273 bps to 4.22% in 2023, then jumped by 412 bps to 21.6% in 2024, then plunged by 124 bps to 5.1% in 2025, then jumped by 432 bps to 16.92% in 2026.
- The last three Operating Margin figures came in at 16.92% (Q1 2026), 5.1% (Q4 2025), and 6.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 11.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.21% |
| Mar 31, 2026 | 16.92% |
| Dec 31, 2025 | -5.10% |
| Sep 30, 2025 | -6.02% |
| Jun 30, 2025 | 33.55% |
| Mar 31, 2025 | 30.05% |
| Dec 31, 2024 | 21.60% |
| Sep 30, 2024 | 15.27% |
| Jun 30, 2024 | 16.92% |
| Mar 31, 2024 | 13.63% |
| Dec 31, 2023 | 4.22% |
| Sep 30, 2023 | 5.25% |
| Jun 30, 2023 | 11.01% |
| Mar 31, 2023 | 10.46% |
| Dec 31, 2022 | -2.43% |
| Sep 30, 2022 | -0.48% |
| Jun 30, 2022 | 7.33% |
| Mar 31, 2022 | 26.44% |
| Dec 31, 2021 | -14.65% |
| Sep 30, 2021 | -13.02% |